Open main menu

Psychiatrienet β

Haloperidol LA-Lurasidone

Haloperidol
long acting
Type Antipsychotic
Group Butyrophenones
links
ATC-code N05AD01
Medscape Haloperidol
PubChem 3559
PubMed Haloperidol
Drugs.com haloperidol
Kompas (Dutch) Haloperidol
Wikipedia Haloperidol
Lurasidone
Type Antipsychotic
Group Atypical AP
links
Medscape Lurasidone
PubMed Lurasidone
Kompas (Dutch) Lurasidone
Wikipedia Lurasidone

Switch medication from Haloperidol LA to Lurasidone.[4] [5]

Nietinrijdenbord.png Stop Haloperidol LA
  • Day 1: Last depot injection
Eenrichtingbord.png Start Lurasidone
  • Week 1-3: approx. 25% of target dose
  • Week 4-6: approx. 50% of target dose
  • Week 7-9: approx. 75% of target dose
  • Week 10: target dose
Infobord.png More information
  • More information on switching to lurasidon: see reference. [6]
    StopDepotStartOral.jpg
Nietinrijdenbord.png — Haloperidol LA
Eenrichtingbord.png — Lurasidone


  1. WHO Collaborating Centre for Drug Statistics Methodology ATC=N05AD01
  2. 2.0 2.1 The Lundbeck Institute; Psychotropics; Terminal Plasma Half-lives
  3. 3.0 3.1 Farmacotherapeutisch Kompas; Inleidende Tekst Antipsychotica (dutch)
  4. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  5. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  6. McEvoy JP et al. Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.J Clin Psychiatry. 2013 Feb;74(2):170-9.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.